Mauna Kea Technologies

Equities

ALMKT

FR0010609263

Advanced Medical Equipment & Technology

Market Closed - Euronext Paris Other stock markets 11:35:08 2024-04-25 am EDT			5-day change	1st Jan Change
0.3795 ^EUR	0.00%		-3.68%	-19.43%

Apr. 03	Mauna Kea: first Italian center for Cellvizio	CF
Mar. 27	Mauna Kea Technologies Partners with V7 to Develop Innovative AI Applications with Cellvizio	CI

Mauna Kea Technologies SA Provides Sales Guidance for the Third Quarter of 2020

September 22, 2020 at 11:45 am EDT

Mauna Kea Technologies SA provided sales guidance for the third quarter of 2020. For the quarter, Preliminary sales for the third quarter of 2020 are expected in a range of €1.8 million to €2.0 million, representing growth of approximately 2% to 11% year-over-year.

Latest news about Mauna Kea Technologies

Mauna Kea: first Italian center for Cellvizio	Apr. 03	CF
Mauna Kea Technologies Partners with V7 to Develop Innovative AI Applications with Cellvizio	Mar. 27	CI
Mauna Kea: partnership with Metrodora Institute in the USA	Mar. 06	CF
Mauna Kea Technologies Partners with Metrodora to Create First U.S. Center of Excellence for the Use of Cellvizio® to Identify and Treat Food Intolerance in Adults	Mar. 06	CI
Mauna Kea: Johnson & Johnson Innovation below 20% threshold	Nov. 24	CF
Mauna Kea Technologies to Receive EUR6 Million Investment from Telix Pharmaceuticals	Nov. 13	MT
Mauna Kea: share price surges as Telix acquires 19% stake	Nov. 13	CF
Telix Pharmaceuticals Limited and Mauna Kea Technologies SA to Expand Collaboration in Urologic Oncology Surgery	Nov. 13	CI
Mauna Kea Technologies SA announced that it expects to receive ?6 million in funding from Telix Pharmaceuticals Limited	Nov. 12	CI
Mauna Kea Technologies Announces First Patient Enrolled in the Pivotal CLEVER Clinical Trial in Peripheral Lung Cancer	Nov. 02	CI
Mauna Kea Technologies Reports Sales Results for the Third Quarter and Nine Months Ended September 30, 2023	23-10-19	CI
Mauna Kea: positive results in pneumology boost share price	23-10-17	CF
Mauna Kea Technologies SA Reports Earnings Results for the Half Year Ended June 30, 2023	23-09-28	CI
Mauna Kea: 1200 Cellvizio procedures completed at EIH	23-09-19	CF
Mauna Kea Technologies and Endoscopy Institute of Hawaii Achieve 1,200 Procedure Milestone	23-09-19	CI
Mauna Kea: transfer to Euronext Growth on August 8	23-08-04	CF
Mauna Kea Technologies to Transfer Shares to Euronext Growth Paris	23-08-04	MT
Transcript : Mauna Kea Technologies SA, H1 2023 Sales/ Trading Statement Call, Jul 20, 2023	23-07-20
Mauna Kea: Cellvizio platform installed in Ireland	23-07-04	CF
Mauna Kea Technologies Announces the Installation of Cellvizio at University College Cork - APC Microbiome Ireland for Inflammatory Bowel Disease Applications	23-07-03	CI
Lysogene CFO Assumes Same Role at Mauna Kea Technologies	23-06-14	MT
Mauna Kea appoints new CFO	23-06-13	CF
Mauna Kea Technologies Appoints Côme de La Tour du Pin as Member of the Executive Committee	23-06-13	CI
Mauna Kea Technologies Appoints Côme de La Tour du Pin as its Chief Financial Officer	23-06-13	CI
Mauna Kea Technologies Shareholders Approve Transfer of Listing to Euronext Growth Paris	23-06-09	MT

Chart Mauna Kea Technologies

Duration

Period

More charts

Company Profile

Mauna Kea Technologies specializes in designing, developing, and selling optical biopsy devices and tools. The group's products are intended for visualizing and detecting cellular abnormalities during the gastrointestinal and pulmonary endoscopic procedures, primarily in cancer patients. Net sales break down by activity as follows: - sales of accessories (41.9%): mini-probes, software, etc.; - sales of system (39.8%); - services (18.3%). Net sales are distributed geographically as follows: the United States and Canada (56.2%), Asia/Pacific (5.4%), Europe-Middle East-Africa and other (38.4%).

Sector

Advanced Medical Equipment & Technology

Calendar

2024-04-24 - Q1 2024 Sales and Revenue Release

More about the company

Income Statement Evolution

More financial data

Ratings for Mauna Kea Technologies

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

0.3795 EUR

Average target price

1.955 EUR

Spread / Average Target

+415.15%

Consensus

EPS Revisions

Estimates Revisions

Quarterly revenue - Rate of surprise

Company calendar

Sector Medical Diagnostic & Testing Equipment

	1st Jan change	Capi.
MAUNA KEA TECHNOLOGIES	-19.43%	24.96M
SARTORIUS AG	-15.34%	19.18B
QUIDELORTHO CORPORATION	-46.58%	2.73B
INNER MONGOLIA FURUI MEDICAL SCIENCE CO., LTD.	+14.09%	1.84B
SHANGHAI MICROPORT EP MEDTECH CO., LTD.	-3.39%	1.61B
BIOTAGE AB	+23.19%	1.18B
SHANGHAI AOHUA PHOTOELECTRICITY ENDOSCOPE CO., LTD.	-10.58%	1B
CONTEC MEDICAL SYSTEMS CO.,LTD	-21.72%	898M
REVENIO GROUP OYJ	-12.15%	710M
VAREX IMAGING CORPORATION	-17.56%	694M

Medical Diagnostic & Testing Equipment